NASDAQ:MIRM

Mirum Pharmaceuticals - MIRM Stock Forecast, Price & News

$25.00

+0.25 (+1.01%)

(As of 08/12/2022 12:00 AM ET)

Add

Compare

Today's Range: $24.53
▼
$25.37
50-Day Range: $18.42
▼
$29.44
52-Week Range: $12.82
▼
$30.55

Volume: 293,868 shs
Average Volume: 224,527 shs
Market Capitalization: $795.88 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $51.80

Mirum Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.20 Rating Score
Upside/Downside: 102.4% Upside
$50.60 Price Target
Short Interest: Bearish
11.52% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.46
Upright™ Environmental Score
News Sentiment: 0.89
Based on 13 Articles This Week
Insider Trading: Selling Shares
$962,335 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($4.30) to ($2.87) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

210th out of 1,117 stocks

Pharmaceutical Preparations Industry

95th out of 550 stocks

3.6

Analyst's Opinion

Consensus Rating
Mirum Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $50.60, Mirum Pharmaceuticals has a forecasted upside of 102.4% from its current price of $25.00.
Amount of Analyst Coverage
Mirum Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
11.52% of the float of Mirum Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Mirum Pharmaceuticals has a short interest ratio ("days to cover") of 8.1.
Change versus previous month
Short interest in Mirum Pharmaceuticals has recently increased by 0.47%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Mirum Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Mirum Pharmaceuticals does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Mirum Pharmaceuticals has received a 62.33% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases ", "Liver-disease medication (A05)", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Mirum Pharmaceuticals is -1.46.

3.3

News and Social Media Coverage

News Sentiment
Mirum Pharmaceuticals has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 13 news articles for Mirum Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for MIRM on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
MarketBeat Follows
6 people have added Mirum Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Mirum Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $962,335.00 in company stock.
Percentage Held by Insiders
33.27% of the stock of Mirum Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
87.68% of the stock of Mirum Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Mirum Pharmaceuticals are expected to grow in the coming year, from ($4.30) to ($2.87) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Mirum Pharmaceuticals is -15.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Mirum Pharmaceuticals is -15.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Mirum Pharmaceuticals has a P/B Ratio of 7.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

Mirum Pharmaceuticals Stock Performance

MIRM Stock traded up $0.25 during midday trading on Friday, reaching $25.00. 293,868 shares of the company were exchanged, compared to its average volume of 224,527. Mirum Pharmaceuticals has a 1-year low of $12.82 and a 1-year high of $30.55. The stock's 50-day simple moving average is $22.77 and its 200 day simple moving average is $23.01. The company has a market cap of $795.88 million, a price-to-earnings ratio of -15.03 and a beta of 1.44.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.84) earnings per share for the quarter, topping analysts' consensus estimates of ($1.05) by $0.21. Mirum Pharmaceuticals had a negative net margin of 137.85% and a negative return on equity of 139.72%. The company had revenue of $17.48 million for the quarter, compared to analysts' expectations of $15.67 million. On average, research analysts anticipate that Mirum Pharmaceuticals will post -4.3 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on MIRM shares. HC Wainwright decreased their price target on shares of Mirum Pharmaceuticals from $69.00 to $63.00 and set a "buy" rating for the company in a research note on Thursday. SVB Leerink lifted their price target on shares of Mirum Pharmaceuticals from $50.00 to $52.00 and gave the stock an "outperform" rating in a research note on Tuesday, May 24th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Mirum Pharmaceuticals currently has an average rating of "Buy" and an average price target of $50.60.

Insiders Place Their Bets

In other news, major shareholder James E. Flynn sold 38,478 shares of Mirum Pharmaceuticals stock in a transaction on Monday, June 6th. The shares were sold at an average price of $25.01, for a total value of $962,334.78. Following the transaction, the insider now directly owns 1,540,190 shares of the company's stock, valued at approximately $38,520,151.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 33.27% of the stock is owned by corporate insiders.

Receive MIRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MIRM Stock News Headlines

August 12, 2022 | finance.yahoo.com

Mirum Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock

August 10, 2022 | markets.businessinsider.com

Here's Why Mirum Pharmaceuticals Stock Is Getting Hammered

August 10, 2022 | nasdaq.com

Mirum Pharma Prices Public Offering Of 3.48 Mln Shares At $23.00/shr; Stock Down

August 8, 2022 | finance.yahoo.com

Earnings Update: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Just Reported And Analysts Are Trimming Their Forecasts

August 7, 2022 | seekingalpha.com

Mirum Pharmaceuticals, Inc. (MIRM) CEO Chris Peetz on Q2 2022 Results - Earnings Call Transcript

August 6, 2022 | benzinga.com

Recap: Mirum Pharmaceuticals Q2 Earnings

August 4, 2022 | finance.yahoo.com

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates

August 4, 2022 | finance.yahoo.com

Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

August 4, 2022 | americanbankingnews.com

Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Down 5.2%

July 28, 2022 | finance.yahoo.com

Mirum Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022

July 28, 2022 | finance.yahoo.com

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: Should You Buy?

July 27, 2022 | finance.yahoo.com

Mirum Pharmaceuticals (NASDAQ:MIRM) climbs 9.6% this week, taking three-year gains to 85%

July 20, 2022 | americanbankingnews.com

Mirum Pharmaceuticals (NASDAQ:MIRM) Trading Down 2.6%

June 24, 2022 | nasdaq.com

Mirum Pharma Presents Data Showing Impact Of LIVMARLI On Patients With Alagille Syndrome

June 24, 2022 | finance.yahoo.com

Mirum Pharmaceuticals Highlights Data Demonstrating Impact of LIVMARLI® (maralixibat) on Patients with Alagille Syndrome at European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting

June 13, 2022 | finance.yahoo.com

Mirum Pharmaceuticals to Showcase LIVMARLI® (maralixibat) Data at EASL and ESPGHAN Annual Congresses

June 6, 2022 | finance.yahoo.com

Mirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors

May 27, 2022 | seekingalpha.com

Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent

May 23, 2022 | seekingalpha.com

Mirum acquires San Diego-based Satiogen in stock and cash combination

May 23, 2022 | finance.yahoo.com

Mirum Pharmaceuticals Acquires Satiogen Pharmaceuticals

May 23, 2022 | finance.yahoo.com

Mirum Pharma Acquires Its Licensing Partner In Cash and Stock

May 7, 2022 | seekingalpha.com

Mirum Pharmaceuticals, Inc. (MIRM) CEO Chris Peetz on Q1 2022 Results - Earnings Call Transcript

May 6, 2022 | seekingalpha.com

Mirum Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation

May 5, 2022 | investing.com

Mirum Pharmaceuticals, Inc. Tops Q1 EPS by 17c

May 5, 2022 | finance.yahoo.com

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MIRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MIRM Company Calendar

Last Earnings: 8/04/2022
Today: 8/13/2022
Next Earnings (Estimated): 11/21/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MIRM
CUSIP: N/A
CIK: 1759425
Web: mirumpharma.com
Phone: (650) 667-4085
Fax: N/A
Employees: 137
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $50.60
High Stock Price Forecast: $74.00
Low Stock Price Forecast: $30.00
Forecasted Upside/Downside: +107.2%
Consensus Rating: Buy
Rating Score (0-4): 3.20
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.65)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-83,990,000.00
Net Margins: -137.85%
Pretax Margin: -154.82%
Return on Equity: -139.72%
Return on Assets: -50.09%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.26
Quick Ratio: 3.16

Sales & Book Value

Annual Sales: $19.14 million
Price / Sales: 41.58
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.38 per share
Price / Book: 7.40

Miscellaneous

Outstanding Shares: 31,835,000
Free Float: 21,243,000
Market Cap: $795.88 million
Optionable: Not Optionable
Beta: 1.44

Key Executives

Mr. Christopher Peetz (Age 43)
Pres, CEO & Director
Comp: $1.02M
Dr. Ian Clements (Age 53)
Chief Financial Officer
Comp: $649.1k
Mr. Peter Radovich M.B.A. (Age 44)
Ph.D., Chief Operating Officer
Comp: $649.1k
Mr. Paul K. Ross
Chief Compliance Officer
Ms. Erin Campany (Age 54)
Sr. VP of HR
Dr. Pamela Vig Ph.D. (Age 51)
Head of R&D
Ms. Lara Longpre MBA (Age 52)
MSC, Chief Devel. Officer
Ms. Vinita P. Kumar
Sr. vice Pres of Quality

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MIRM Stock - Frequently Asked Questions

Should I buy or sell Mirum Pharmaceuticals stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirum Pharmaceuticals in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MIRM shares.
View MIRM analyst ratings or view top-rated stocks.
What is Mirum Pharmaceuticals' stock price forecast for 2022?: 5 brokerages have issued 1-year target prices for Mirum Pharmaceuticals' stock. Their MIRM share price forecasts range from $30.00 to $74.00. On average, they anticipate the company's share price to reach $50.60 in the next year. This suggests a possible upside of 102.3% from the stock's current price.
View analysts price targets for MIRM or view top-rated stocks among Wall Street analysts.
How have MIRM shares performed in 2022?: Mirum Pharmaceuticals' stock was trading at $15.95 at the beginning of 2022. Since then, MIRM stock has increased by 56.8% and is now trading at $25.01.
View the best growth stocks for 2022 here.
When is Mirum Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our MIRM earnings forecast.
How were Mirum Pharmaceuticals' earnings last quarter?: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) announced its earnings results on Thursday, August, 4th. The company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.21. The company earned $17.48 million during the quarter, compared to the consensus estimate of $15.67 million. Mirum Pharmaceuticals had a negative trailing twelve-month return on equity of 139.72% and a negative net margin of 137.85%.
What other stocks do shareholders of Mirum Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Mirum Pharmaceuticals investors own include Pfizer (PFE), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Vaxart (VXRT), Advanced Micro Devices (AMD), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV) and Dynavax Technologies (DVAX).

When did Mirum Pharmaceuticals IPO?: (MIRM) raised $75 million in an IPO on Thursday, July 18th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers.
What is Mirum Pharmaceuticals' stock symbol?: Mirum Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIRM."
Who are Mirum Pharmaceuticals' major shareholders?: Mirum Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Franklin Resources Inc. (3.92%), Integral Health Asset Management LLC (0.56%), Russell Investments Group Ltd. (0.25%), Deutsche Bank AG (0.24%), Victory Capital Management Inc. (0.17%) and Calamos Advisors LLC (0.13%). Insiders that own company stock include Christopher Peetz, Edwin Jonathan Tucker, Ian Clements, James E Flynn, John A Maurer, Laurent Fischer and Pamela Vig.
View institutional ownership trends.
How do I buy shares of Mirum Pharmaceuticals?: Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Mirum Pharmaceuticals' stock price today?: One share of MIRM stock can currently be purchased for approximately $25.01.
How much money does Mirum Pharmaceuticals make?: Mirum Pharmaceuticals (NASDAQ:MIRM) has a market capitalization of $818.83 million and generates $19.14 million in revenue each year. The company earns $-83,990,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis.
How many employees does Mirum Pharmaceuticals have?: The company employs 137 workers across the globe.
How can I contact Mirum Pharmaceuticals?: Mirum Pharmaceuticals' mailing address is 950 TOWER LANE SUITE 1050, FOSTER CITY CA, 94404. The official website for the company is mirumpharma.com. The company can be reached via phone at (650) 667-4085 or via email at ir@mirumpharma.com.

This page (NASDAQ:MIRM) was last updated on 8/13/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Mirum Pharmaceuticals - MIRM Stock Forecast, Price & News

Mirum Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals Stock Performance

Wall Street Analyst Weigh In

Insiders Place Their Bets

MIRM Stock News Headlines

MIRM Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

MIRM Stock - Frequently Asked Questions

Should I buy or sell Mirum Pharmaceuticals stock right now?

What is Mirum Pharmaceuticals' stock price forecast for 2022?

How have MIRM shares performed in 2022?

When is Mirum Pharmaceuticals' next earnings date?

How were Mirum Pharmaceuticals' earnings last quarter?

What other stocks do shareholders of Mirum Pharmaceuticals own?

When did Mirum Pharmaceuticals IPO?

What is Mirum Pharmaceuticals' stock symbol?

Who are Mirum Pharmaceuticals' major shareholders?

How do I buy shares of Mirum Pharmaceuticals?

What is Mirum Pharmaceuticals' stock price today?

How much money does Mirum Pharmaceuticals make?

How many employees does Mirum Pharmaceuticals have?

How can I contact Mirum Pharmaceuticals?

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™